Effect of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs

Pharmacological Research

Volumn 46, Issue 5, 2002, Pages 375-381

  Yatsu, Takeyuki ^a   Kusayama, Toshiyuki ^a   Tomura, Yuichi ^a   Arai, Yukinori ^a   Aoki, Motonori ^a   Tahara, Atsuo ^a   Wada, Koh Ichi ^a   Tsukada, Junko ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cardiac dysfunction; Conivaptan; V1a and V2 receptors; Vasopressin receptor antagonist

Indexed keywords

ARGIPRESSIN; CONIVAPTAN; PENTOBARBITAL; VASOPRESSIN RECEPTOR ANTAGONIST; BENZAZEPINE DERIVATIVE; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; VASCULAR RESISTANCE; VASOCONSTRICTION; ANESTHESIA; ANIMAL; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION;

ANESTHESIA; ANIMALS; BENZAZEPINES; CARDIAC OUTPUT; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMODYNAMIC PROCESSES; INFUSIONS, INTRAVENOUS; MALE; RECEPTORS, VASOPRESSIN; VASOPRESSINS;

EID: 0036433079     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043661802002062     Document Type: Article

References (45)

1. Wenzel V, Lindner KH. Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor. Cardiovasc Res 2001; 51: 529-41.
2. Francis GS. Neuroendocrine manifestations of congestive heart failure. Am J Cardiol 1988; 62: 9A-13A.
3. Parmley WW. Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol 1989; 13: 771-85.
4. Cohn JN. Current therapy of the failing heart. Circulation 1988; 78: 1099-107.
5. Packer M. Therapeutic options in the management of chronic heart failure: Is there a drug of first choice? Circulation 1989; 79: 198-204.
6. Packer M. Treatment of chronic heart failure. Lancet 1992; 340: 92-5.
7. 1 receptor agonist, in a canine model of acute congestive heart failure. Gen Pharmacol 1998; 30: 733-7.
8. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999; 376: 239-46.
9. Schrier RW, Abdallah JG, Weinberger HHD, Abraham WT. Therapy of heart failure. Kidney Int 2000; 57: 1418-25.
10. Fox AW. Vascular vasopressin receptors. Gen Pharmacol 1988; 19: 639-47.
11. Butlen D, Guillon G, Rajerison RM, Jard S, Sawyer WH, Manning M. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: Effects of highly potent analogues and competitive inhibitors. Mol Pharmacol 1978; 14: 1006-17.
12. Riegger GA, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 1982; 72: 49-52.
13. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997; 282: 301-8.
14. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998; 38: 198-205.
15. Tomura Y, Tahara A, Tsukada J, Yatsu T, Uchida W, Iizumi Y, Honda K. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin Exp Pharmacol Physiol 1999; 26: 399-403.
16. 2 receptor antagonist (YM087) in the rat. Eur J Pharmacol 1999; 381: 23-30.
17. 2 receptors: Synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl) benzanilide derivatives and 4′-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl) benzanilide derivatives. Chem Pharm Bull 2000; 48: 21-31.
18. 2 receptor antagonist, in dogs. Eur J Pharmacol 1997; 321: 225-30.
19. 2 receptor antagonist. Naunyn Shmiedebergs Arch Pharmacol 1998; 357: 63-9.
20. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol 1998; 125: 1463-70.
21. 2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 1999; 55: 633-7.
22. Laszlo FA, Laszlo F Jr, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 1991; 43: 73-108.
23. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258: F973-9.
24. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. New Engl J Med 1981; 305: 263-6.
25. Boyle WA, Segel LD. Direct cardiac effects of vasopressin and their reversal by a vascular antagonist. Am J Physiol 1986; 251: H734-41.
26. Lee RW, Standaert S, Lancaster LD, Buckley D, Goldman S. Cardiac and peripheral circulatory responses to angiotensin and vasopressin in dogs. J Clin Invest 1988; 82: 413-9.
27. Robinson JL. Effect of vasopressin and phenylephrine on arterial pressure and heart rate in conscious dogs. Am J Physiol 1986; 251: H253-60.
28. Cartheuser CF, Komarek J. Effects of vasopressin on the circulation, myocardial dynamics, and left ventricular oxygen consumption in the anaesthetized dog. Basic Res Cardiol 1980; 75: 668-82.
29. Raya TE, Gay RG, Goldman S. Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilatation. J Pharmacol Exp Ther 1990; 255: 1015-20.
30. Arnolda L, McGrath BP, Cocks M, Johnston CI. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J Clin Invest 1986; 78: 674-9.
31. Arnolda L, McGrath BP, Johnston CI. Systemic and regional effects of vasopressin and angiotensin in acute left ventricular failure. Am J Physiol 1991; 260: H499-506.
32. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986; 7: 758-65.
33. Nicod P, Waeber B, Bussien JP, Goy JJ, Turini G, Nussberger J, Hofbauer KG, Brunner HR. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol 1985; 55: 1043-7.
34. Nicod P, Biollaz J, Waeber B, Goy JJ, Polikar R, Schlapfer J, Schaller MD, Turini GA, Nussberger J, Hofbauer KG, Brunner HR. Hormonal, global, and regional haemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatraemia. Br Heart J 1986; 56: 433-9.
35. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephritic syndrome, cirrhosis, and pregnancy. 1. New Engl J Med 1988; 319: 1065-72.
36. Fujisawa G, Ishikawa S, Okada K, Sakuma N, Tsuboi Y, Saito T. Improvement by a nonpeptide vasopressin antagonist OPC-31260 of water retention in experimental rats with myocardial infarction. J Am Soc Nephrol 1993; 4: 852 [Abstract].
37. Xu DL, Martin PY, Ohara M, St John J, Pattison T, Meng X, Morris K, Kim JK, Schrier RW. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 1997; 99: 1500-5.
38. Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A, Nakamoto H, Oka K, Yamamura Y, Saruta T. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994; 267: H2245-54.
39. Phillips PA, Burrel LM, Gow CB, Johnston CI, Grant S, Risvanis J, Aldred K. Vasopressin antagonism: Physiological and pharmacological roles. In: Saito T, Kurokawa K, Yoshida S, eds. Neurohypophysis recent progress of vasopressin and oxytocin research. Amsterdam: Elsevier, 1995: 643-58.
40. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patient with chronic congestive heart failure. New Engl J Med 1984; 311: 819-23.
41. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patient with severe chronic heart failure. Circulation 1986; 73: 257-67.
42. Kumar S, Berl T. Sodium. Lancet 1998; 352: 220-8.
43. Mayinger B, Hensen J. Nonpeptide vasopressin antagonists: A new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes 1999; 107: 157-65.
44. 2 vasopressin antagonist YM087. Circulation 1999; 100(Suppl): I-299.
45. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-23.